TN2015000090A1 - Daptomycin formulations and uses thereof - Google Patents
Daptomycin formulations and uses thereofInfo
- Publication number
- TN2015000090A1 TN2015000090A1 TNP2015000090A TN2015000090A TN2015000090A1 TN 2015000090 A1 TN2015000090 A1 TN 2015000090A1 TN P2015000090 A TNP2015000090 A TN P2015000090A TN 2015000090 A TN2015000090 A TN 2015000090A TN 2015000090 A1 TN2015000090 A1 TN 2015000090A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pharmaceutically acceptable
- daptomycin formulations
- methods
- lyophilized daptomycin
- formulations
- Prior art date
Links
- 108010013198 Daptomycin Proteins 0.000 title abstract 5
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title abstract 5
- 229960005484 daptomycin Drugs 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 150000002303 glucose derivatives Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699570P | 2012-09-11 | 2012-09-11 | |
| US201361839699P | 2013-06-26 | 2013-06-26 | |
| PCT/IB2013/002191 WO2014041425A1 (fr) | 2012-09-11 | 2013-09-11 | Formulations de daptomycine et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2015000090A1 true TN2015000090A1 (en) | 2016-06-29 |
Family
ID=50277707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2015000090A TN2015000090A1 (en) | 2012-09-11 | 2015-03-10 | Daptomycin formulations and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9655946B2 (fr) |
| EP (2) | EP2895187A4 (fr) |
| AU (2) | AU2013316779A1 (fr) |
| BR (1) | BR112015005400B1 (fr) |
| CA (1) | CA2884484C (fr) |
| CL (1) | CL2015000608A1 (fr) |
| CY (1) | CY2200004T2 (fr) |
| DE (1) | DE13837694T1 (fr) |
| DK (1) | DK2895187T1 (fr) |
| ES (2) | ES3018415T3 (fr) |
| HK (1) | HK1207006A1 (fr) |
| HU (2) | HUE071031T2 (fr) |
| IL (1) | IL237652B (fr) |
| MX (1) | MX366122B (fr) |
| NZ (3) | NZ742241A (fr) |
| PL (1) | PL4066849T3 (fr) |
| SA (1) | SA515360129B1 (fr) |
| SG (1) | SG11201506113WA (fr) |
| TN (1) | TN2015000090A1 (fr) |
| WO (1) | WO2014041425A1 (fr) |
| ZA (1) | ZA201502310B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655946B2 (en) * | 2012-09-11 | 2017-05-23 | Hospira Australia Pty Ltd. | Daptomycin formulations and uses thereof |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| EP3528786B1 (fr) | 2016-10-21 | 2023-04-05 | Xellia Pharmaceuticals ApS | Formulations liquides de daptomycine |
| JP7229999B2 (ja) * | 2017-08-31 | 2023-02-28 | クセリア ファーマシューティカルズ エーピーエス | ダプトマイシン製剤 |
| CN110339342A (zh) * | 2018-04-03 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 一种达托霉素的盐或含盐的组合物及其制备方法 |
| US11058745B1 (en) | 2018-10-04 | 2021-07-13 | Good Health, Llc | Stable liquid pharmaceutical compositions of daptomycin |
| CN114828873A (zh) * | 2019-12-26 | 2022-07-29 | 尼普洛株式会社 | 含有达托霉素的稳定的冷冻干燥制剂 |
| BR112022014553A2 (pt) | 2020-02-03 | 2022-09-20 | Genzyme Corp | Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic |
| CN115243675A (zh) | 2020-03-12 | 2022-10-25 | 巴克斯特国际公司 | 含有山梨糖醇和甘露糖醇的组合的达托霉素制剂 |
| MX2023001014A (es) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Composiciones farmaceuticas que comprenden venglustat. |
| CN115590825B (zh) * | 2022-10-20 | 2024-02-02 | 安士制药(中山)有限公司 | 一种注射用达托霉素及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5560906A (en) * | 1995-03-27 | 1996-10-01 | Oral Technology Laboratories, Inc. | Non-alcoholic antimicrobial mouthwash for removal of dental plaque |
| SI1115417T1 (sl) * | 1998-09-25 | 2006-08-31 | Cubist Pharm Inc | Uporaba daptomicina |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| WO2002059145A1 (fr) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Procedes de preparation de lipopeptides purifies |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| CN1616083A (zh) | 2004-09-01 | 2005-05-18 | 魏雪纹 | 注射用达托霉素冻干制剂及制备方法 |
| US8003673B2 (en) * | 2005-05-31 | 2011-08-23 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
| JP2013511522A (ja) * | 2009-11-23 | 2013-04-04 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ダプトマイシン製剤 |
| DK2504353T4 (da) | 2009-11-23 | 2023-11-20 | Cubist Pharmaceuticals Llc | Lipopeptidsammensætninger og tilsvarende fremgangsmåder |
| ES2655215T3 (es) * | 2012-08-23 | 2018-02-19 | Mylan Laboratories Ltd. | Mejoramiento de la formulación inyectable de daptomicina |
| US9655946B2 (en) * | 2012-09-11 | 2017-05-23 | Hospira Australia Pty Ltd. | Daptomycin formulations and uses thereof |
-
2013
- 2013-09-11 US US14/427,618 patent/US9655946B2/en active Active
- 2013-09-11 EP EP13837694.2A patent/EP2895187A4/fr not_active Withdrawn
- 2013-09-11 HU HUE22169277A patent/HUE071031T2/hu unknown
- 2013-09-11 AU AU2013316779A patent/AU2013316779A1/en not_active Abandoned
- 2013-09-11 MX MX2015003164A patent/MX366122B/es active IP Right Grant
- 2013-09-11 DK DK13837694.2T patent/DK2895187T1/da unknown
- 2013-09-11 NZ NZ742241A patent/NZ742241A/en unknown
- 2013-09-11 NZ NZ706286A patent/NZ706286A/en unknown
- 2013-09-11 ES ES22169277T patent/ES3018415T3/es active Active
- 2013-09-11 SG SG11201506113WA patent/SG11201506113WA/en unknown
- 2013-09-11 DE DE13837694.2T patent/DE13837694T1/de active Pending
- 2013-09-11 NZ NZ74134213A patent/NZ741342A/en unknown
- 2013-09-11 PL PL22169277.5T patent/PL4066849T3/pl unknown
- 2013-09-11 WO PCT/IB2013/002191 patent/WO2014041425A1/fr not_active Ceased
- 2013-09-11 EP EP22169277.5A patent/EP4066849B1/fr active Active
- 2013-09-11 CA CA2884484A patent/CA2884484C/fr active Active
- 2013-09-11 HK HK15107795.5A patent/HK1207006A1/xx unknown
- 2013-09-11 ES ES13837694.2T patent/ES2552754T1/es active Pending
- 2013-09-11 BR BR112015005400-5A patent/BR112015005400B1/pt active IP Right Grant
-
2015
- 2015-03-10 IL IL237652A patent/IL237652B/en active IP Right Grant
- 2015-03-10 TN TNP2015000090A patent/TN2015000090A1/fr unknown
- 2015-03-11 CL CL2015000608A patent/CL2015000608A1/es unknown
- 2015-03-11 SA SA515360129A patent/SA515360129B1/ar unknown
- 2015-04-07 ZA ZA2015/02310A patent/ZA201502310B/en unknown
- 2015-11-11 HU HUE13837694A patent/HUE13837694T1/hu unknown
- 2015-11-20 CY CY20152200004T patent/CY2200004T2/el unknown
-
2017
- 2017-04-20 US US15/492,111 patent/US20170216396A1/en not_active Abandoned
-
2018
- 2018-02-23 US US15/903,764 patent/US10357535B2/en active Active
- 2018-08-17 AU AU2018217322A patent/AU2018217322B2/en active Active
-
2020
- 2020-04-15 US US16/849,387 patent/US20200237858A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000090A1 (en) | Daptomycin formulations and uses thereof | |
| WO2013184755A3 (fr) | Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation | |
| MY188541A (en) | Besifloxacin for the treatment of resistant acne | |
| WO2014052836A3 (fr) | Procédés et compositions de traitement d'une infection | |
| NZ702744A (en) | D-amino acid compounds for liver disease | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX349827B (es) | Compuestos que contienen nitrogeno y su uso. | |
| PH12018500071A1 (en) | Plinabulin compositions | |
| PH12015501588B1 (en) | Compounds and methods for treating bacterial infections | |
| PH12015500900B1 (en) | A stabilized pemetrexed formulation | |
| PH12013501452A1 (en) | Omv vaccine against burkholderia infections | |
| PH12015501088A1 (en) | Dimeric compounds | |
| UA115357C2 (uk) | Похідні піридин-4-ілу | |
| WO2014022382A3 (fr) | Inhibiteurs de protéine kinase antibactérienne | |
| MX363631B (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
| IN2013MU03216A (fr) | ||
| AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
| MA37956A1 (fr) | Formulations de daptomycine et leurs utilisations | |
| PH12013501069A1 (en) | Pharmaceutical compositions | |
| UA91125U (uk) | Антибактеріальна композиція | |
| UA83604U (en) | Pharmaceutical composition | |
| UA76716U (uk) | 5,7-ДИМЕТИЛ-2-ОКСО-6-ФЕНІЛАЗО-ТІАЗОЛО[4,5-b]ПІРИДИН-3-ІЛГІДРАЗОНИ АЦЕТАТНОЇ КИСЛОТИ, ЩО ПРОЯВЛЯЮТЬ АНТИЕКСУДАТИВНУ ДІЮ |